Cargando…
Herpetrione, a New Type of PPARα Ligand as a Therapeutic Strategy Against Nonalcoholic Steatohepatitis
Non-alcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), is a leading cause of cirrhosis and liver cancer worldwide; nevertheless, there are no Food and Drug Administration-approved drugs for treating NASH until now. Peroxisome proliferator-activated receptor alpha (PPARα)...
Autores principales: | Linghu, Lang, Zong, Wei, Liao, Yixuan, Chen, Qianyu, Meng, Fancheng, Wang, Guowei, Liao, Zhihua, Lan, Xiaozhong, Chen, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AAAS
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687582/ https://www.ncbi.nlm.nih.gov/pubmed/38034083 http://dx.doi.org/10.34133/research.0276 |
Ejemplares similares
-
TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis
por: Zhang, Yanmei, et al.
Publicado: (2021) -
Oxybaphus himalaicus Mitigates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting TLR4/MD2 Complex Formation
por: Zhan, Honghong, et al.
Publicado: (2022) -
Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγ in a Rat Model
por: Susutlertpanya, Warinda, et al.
Publicado: (2015) -
PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022) -
Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats
por: Xing, Yu-feng, et al.
Publicado: (2016)